| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 556.46 | 3.5% | 26.5% |
| Total Income | 564.84 | 2.2% | 25.8% |
| Expenditure | 422.38 | 4.2% | 12.0% |
| PBT | 134.17 | 19.7% | 87.3% |
| Net Profit | 100.38 | 19.7% | 86.4% |
| OPM | 32.27% | 5.14pp | 31.06pp |
| NPM | 17.77% | 2.60pp | 5.77pp |
| EPS | 4.77 | 18.9% | 65.0% |
Sai Life Sciences Announces Q3FY26 Results: Revenue Up By 43%, EBITDA Up By 79%, Net Profit Up By 199%
06 Feb 2026 · 6 Feb, 2:02 am
Summary
Sai Life Sciences Limited, a CRDMO, announced its financial results for the third quarter and nine months ended December 2025. The company reported significant increases in revenue, EBITDA, and net profit.
Key Highlights
- 1
Revenue from Operations was ₹556 Cr for Q3FY26, an increase of 27%
- 2
EBITDA stood at ₹191 Cr for Q3FY26, an increase of 54%
- 3
PAT stood at ₹100 Cr for Q3FY26, an increase of 86%
- 4
Revenue from Operations was ₹1,590 Cr for 9MFY26, an increase of 43%
- 5
EBITDA stood at ₹472 Cr for 9MFY26, an increase of 79%
- 6
PAT stood at ₹245 Cr for 9MFY26, an increase of 199%
- 7
Applied Al driven retrosynthetic analysis to ML generated compounds
- 8
Successfully delivered a full library of Al designed macrocyclic peptides
- 9
Created a centralized group for Photochemistry and Electrochemistry
- 10
Strengthened Flow capabilities across Discovery & CMC
- 11
Implemented automated permeability measurement platform in Discovery
- 12
Invested ₹405 Cr as on date in capital expenditure
- 13
Successfully completed 8 customer audits across manufacturing and R&D units
- 14
Achieved My Green Lab (MGL) Green-level certification for two PR&D laboratories and two Medicinal Chemistry laboratories
- 15
Published a joint sustainability case study with Bayer on The Climate Drive
Management Comments
Mr. Krishna Kanumuri
Managing Director and CEO, Sai Life Sciences Limited
Q3 FY26 marked continued progress in building Sai Life Sciences into a science-led, globally relevant CRDMO... With disciplined execution and a clear strategic direction, Sai Life Sciences is well positioned to support the next phase of innovation while creating long-term value for all stakeholders.
Mr. Siva Chittor
Chief Financial Officer, Sai Life Sciences Limited
We have delivered a robust growth in Q3 FY26 which outperformed the broader CRDMO industry trend... With strengthened capabilities, a solid order pipeline, and a more resilient operating foundation, we are well positioned for another year of strong and profitable growth, creating enduring value for our stakeholders.
Informational and educational content only. Not investment advice.